Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab-Reference-Cited by-同舟云学术

Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab

Published:2013-11-14 Issue:20 Volume:122 Page:3482-3491
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Golay Josée¹,Da Roit Fabio¹,Bologna Luca¹,Ferrara Claudia²,Leusen Jeanette H.³,Rambaldi Alessandro¹,Klein Christian²,Introna Martino¹

Affiliation:

1. Center of Cellular Therapy “G. Lanzani,” Division of Haematology, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy;

2. Roche Glycart AG, Roche Pharma Research and Early Development, Schlieren, Switzerland; and

3. Immunotherapy Laboratory, Department of Immunology, University Medical Center, Utrecht, The Netherlands

Abstract

Key Points Phagocytosis of CLL targets by neutrophils is a novel mechanism of action of the glycoengineered anti-CD20 antibody obinutuzumab. This mechanism takes place in physiological conditions and requires CD16B and CD32A.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/122/20/3482/1372114/3482.pdf

Reference75 articles.

1. Phase I to III trials of anti-B cell therapy in non-Hodgkin’s lymphoma.;Martin;Clin Cancer Res,2007

2. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.;Salles;Lancet,2011

3. From the bench to the bedside: ways to improve rituximab efficacy.;Cartron;Blood,2004

4. Rituximab: mechanism of action.;Weiner;Semin Hematol,2010

5. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents.;Cragg;Blood,2004

Cited by 198 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of antibody glycosylation in autoimmune and alloimmune kidney diseases;Nature Reviews Nephrology;2024-07-03

2. Obinutuzumab in untreated primary membranous nephropathy: An observational case series;Nephrology;2024-06-03

3. B-cell depletion in autoimmune diseases;Annals of the Rheumatic Diseases;2024-05-22

4. The IgG-specific endoglycosidases EndoS and EndoS2 are distinguished by conformation and antibody recognition;Journal of Biological Chemistry;2024-05

5. Mechanisms of resistance to anti-CD20 antibodies in lymphoid malignancies;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024